Document:

<PAGE>

                                                                Exhibit 4.03 (b)
                                                                ----------------

                            SECURED PROMISSORY NOTE

                            Dated December 15, 2000

     FOR VALUE RECEIVED, the undersigned ("Borrower") hereby promises to pay to
DVI Business Credit Corporation or its assignee (the "Holder") or order, the
principal sum of Seven Million Two Hundred Fifty Thousand Dollars ($7,250,000)
or such amount thereof as may be from time to time advanced hereunder and
pursuant to the terms of that certain Loan and Security Agreement dated as of
the date hereof between Holder as Lender and Borrower as Borrower (as amended
from time to time, the "Agreement"), with interest on the unpaid principal
balance from time to time outstanding until paid at the fluctuating rate of
interest provided in the Agreement; computed on the basis of a 360-day year and
actual days elapsed, until paid. Interest shall be payable on the first of each
month this Note is outstanding in accordance with the terms of the Agreement,
with all unpaid principal and interest due and payable in full on the expiration
of the term of the Agreement. Capitalized terms used but not defined herein
shall have the meanings given them in the Agreement.

     If any part of the interest due on this Note is not paid when due, it shall
be added to the principal amount of this Note and thereafter bear interest at
the rate provided in the Agreement. If the specified interest rate shall at any
time exceed the maximum allowed by law, then the applicable interest rate shall
be reduced to the maximum allowed by law.

     1.   Borrower may only have the right to prepay or terminate this Note if
and when such right is expressly provided for in the Agreement.

     2.   Principal and interest shall be payable to Holder at 4041 MacArthur
Blvd., Suite 401, Newport Beach, CA 92660, or such other place as the Holder
may, from time to time in writing, appoint.

     3.   This Note is made pursuant to, and secured by, the Collateral and the
Agreement. This Note is also secured by all of the other Loan Documents. The
Agreement and the other Loan Documents create a lien on and security interest in
the Collateral. The Agreement and the other Loan Documents are hereby
incorporated by reference in and made a part of this Note.

     4.   The occurrence of any Event of Default shall, at the election of the
Holder, make the entire unpaid balance of the principal amount of this Note and
accrued interest immediately due and payable without notice of default,
presentment or demand for payment, protest or notice of nonpayment or dishonor,
or other notices or demands of any kind or character.

     5.   Failure of the Holder to exercise the acceleration option of paragraph
4 of this Note on the occurrence of any of the events enumerated therein shall
not constitute waiver of the right to exercise such option on the subsequent
occurrence of any of the events enumerated therein.

     6.   Principal and interest shall be payable in lawful money of the United
States of America which shall be legal tender in payment of all debts and dues,
public and private, at the time of payment. Borrower waives presentment, demand
for payment, notice of nonpayment, protest and notice of protest, and all other
notices and demands in connection with the delivery, acceptance, performance,
default or enforcement of this Note. Borrower consents to any and all
assignments of this Note, extensions of time, renewals and waivers that may be
made or granted by the Holder. Borrower expressly agrees that such assignments,
extensions of time, renewals or waivers shall not affect Borrower's liability.
Borrower agrees that Holder may, without notice to Borrower and without
affecting the liability of Borrower, accept additional or substitute security
for this Note, release any security or any party liable for this Note or extend
or renew this Note. Borrower may not assign any of its rights or delegate any of
its obligations under this Note. Any such assignment or delegation by Borrower
shall be void.

     7.   Upon or after and during the continuance of any Event of Default, in
addition to any and all other remedies available to Holder, the outstanding
principal balance of this Note shall bear interest at a variable rate per annum
equal to the Default Interest Rate until the principal balance of this Note is
paid in full.

                                       36
<PAGE>

     8.   If action be instituted on this Note (including without limitation,
any proceedings for collection hereof in any bankruptcy or probate matter or
case), or if proceedings are commenced on or under any of the Loan Documents,
Borrower promises to pay the Holder all costs of collection and enforcement
including, without limitation, reasonable attorneys' fees.

     9.   Any and all notices or other communications or payments required or
permitted to be given hereunder shall be effective when received or refused if
given or rendered in writing, in the manner provided in the Agreement.

     10.  This Note shall inure to the benefit of the Holder's successors and
assigns. References to the "Holder" shall be deemed to refer to the holder(s) of
this Note at the time such reference becomes relevant.

     11.  If any term, provision, covenant, or condition of this Note is held by
a court of competent jurisdiction to be invalid, void, or unenforceable, the
rest of this Note shall remain in full force and effect to the greater extent
permitted by law and shall in no other way be affected, impaired or invalidated.

     12.  Nothing contained herein or in any Loan Document shall be deemed to
prevent recourse to and the enforcement against Borrower and the Collateral of
all liabilities, obligations and undertakings contained herein and in the Loan
Documents.

     13.  THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED UNDER THE LAWS OF THE
STATE OF CALIFORNIA AND BORROWER AGREES TO SUBMIT TO THE JURISDICTION OF THE
STATE AND/OR FEDERAL COURTS IN THE STATE OF CALIFORNIA.

THIS NOTE CONTAINS JURY TRIAL WAIVER AND EXEMPLARY AND PUNITIVE DAMAGES WAIVER
PROVISIONS

<TABLE>
<S>                                                    <C>
OCCUPATIONAL HEALTH + REHABILITATION INC               CM OCCUPATIONAL HEALTH,
                                                       LIMITED LIABILITY COMPANY
                                                       By: Occupational Health + Rehabilitation Inc
                                                       Its Member and Manager

By:    ________________________________                By:    ________________________________
Print Name: ___________________________                Print Name: ___________________________
Title: ________________________________                Title: ________________________________

OHR-SSM, LLC                                           OCCUPATIONAL HEALTH CONNECTION, LLC
By: Occupational Health + Rehabilitation Inc           By:  Occupational Health + Rehabilitation Inc
Its Member and Manager                                 Its Member and Manager

By:    ________________________________                By:    ________________________________
Print Name: ___________________________                Print Name: ___________________________
Title: ________________________________                Title: ________________________________
</TABLE>

                                       37<PAGE>

                                                                   EXHIBIT 10.13

ORCHID BIOSCIENCES, INC. HAS REQUESTED THAT THE MARKED PORTIONS OF THIS DOCUMENT
BE ACCORDED 406 CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 UNDER THE SECURITIES
ACT, AS AMENDED

[*****] CONFIDENTIAL MATERIAL OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. ASTERICKS DENOTE SUCH OMISSIONS

                       Genotyping Collaboration Agreement
--------------------------------------------------------------------------------

      THIS GENOTYPING SERVICE AND COLLABORATION AGREEMENT, dated as of February
12, 2001 (the "Effective Date"), is between ORCHID BIOSCIENCES, INC., a Delaware
corporation having a principal place of business at 303 College Road East,
Princeton, New Jersey 08543 ("Orchid"), and ASTRAZENECA UK, LIMITED, an English
corporation, having its registered office at 15 Stanhope Gate, London, W1K 1LN
("AZ").

      WHEREAS, Orchid develops, manufactures and/or commercializes genetic
diversity products, services and technologies to perform automated SNP analysis
based on its proprietary primer extension technology; and

      WHEREAS, AZ desires to have Orchid provide it with genotyping services as
more fully described in this Agreement;

      NOW THEREFORE, the parties agree as follows:

1. DEFINITIONS.

      For purposes of this Agreement, the following terms have the meanings set
forth below:

      1.1.  "Access Fee" means the one-time, non-creditable fee in the total
            amount of [*****] payable by AZ to Orchid pursuant to Section 2.3
            and subject to 4.13.

      1.2.  "Accuracy Rate" means the achievement of 99% accuracy of genotype
            calls on those assays that fall within the Genotyping Pass Rate. The
            one million genotypes

[*****] CONFIDENTIAL MATERIAL OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. ASTERICKS DENOTE SUCH OMISSIONS

                                       1
<PAGE>

            utilized by Orchid for Formatting purposes are excluded from any
            calculation of Accuracy Rate.

      1.3.  "Affiliate" means any legal entity, directly or indirectly
            controlling, controlled by or under common control with a party to
            this Agreement. For purposes of this Agreement, "control" means the
            direct or indirect ownership of at least fifty percent (50%) of the
            outstanding voting securities of the legal entity, or the right to
            receive at least fifty percent (50%) of the profits or earnings of
            the legal entity, or the right to direct the policy decisions of the
            legal entity.

      1.4.  "Assay Data" and "Formatted SNP Data" means the raw data produced by
            Orchid's performance of the Genotyping Services, including SNP
            conversion data and Genotyping results. Assay Data does not include
            any data derived from the one million genotypes used for Formatting
            ("Formatted SNP Data"), other than whether the SNP passed or failed.
            Information pertaining to these one million genotypes will be
            available upon request from the JSC..

      1.5.  "Assay Development" means the Formatting of each individual SNP into
            a working assay through the custom design and testing of specific
            oligonucleotides for the interrogation of an individual SNP,
            including one set of PCR Primers and one SNP-IT Primer for the
            desired SNP, in conjunction with Genotyping against a known sample
            set.

      1.6.  "AZ SNPs" means up to [*****] and (iii) are submitted by AZ to
            Orchid pursuant to Section 6 with complete sequence information.

      1.7.  "Collaboration" means the Genotyping Studies undertaken by the
            parties after [*****], as determined by the JSC.

      1.8.  "Confidential Information" means all proprietary and confidential
            information and materials, patentable or otherwise, of a party that
            is disclosed by or on behalf of such party (the "Disclosing Party")
            to the other party (the "Receiving Party") including, but not
            limited to, business, technical and financial information, DNA
            sequences and proprietary sequence information, SNPS, SNP detection
            techniques, vectors, cell substances, formulations, techniques,
            methodology, equipment, data, reports, Know-How, technology, sources
            of supply, patent

[*****] CONFIDENTIAL MATERIAL OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. ASTERICKS DENOTE SUCH OMISSIONS

                                       2
<PAGE>

            strategy and business plans, and pharmacogenomic or pharmacogenetic
            applications, procedures and plans.

      1.9.  "DNA Samples" means samples of genomic DNA to be supplied to Orchid
            by AZ under this Agreement in accordance with the criteria set forth
            in Schedule A. For all Genotyping Studies [*****], AZ will provide
            to Orchid up to 1 nanogram of DNA per genotype to be studied. DNA
            Samples will include control DNA Samples as specified in Schedule A.
            The provision of all DNA Samples will be at AZ's sole expense.

      1.10. "First Use" means the reporting of data [*****].

      1.11. "Formatting" means the custom design of PCR and SNP-IT Primers and
            quality control of the Primers for amplification and subsequent
            SNP-IT functionality.

      1.12. "Genotyping" means the process of identifying both alleles of one or
            more SNP sites in a sample using SNP-IT.

      1.13. "Genotyping Pass Rate" means the production of Assay Data on at
            least [*****] of assays that were Successfully Converted. Excluded
            from the calculation of Genotyping Pass Rate are (1) the one million
            genotypes utilized by Orchid for Formatting purposes, and (2) those
            assays that failed as a result of a Non-Assay Failure.

      1.14. "Genotyping Studies" means the services to be performed by Orchid
            for AZ under this Agreement as shall be more fully described in the
            JSC's work plans set forth in Schedule B, consisting of (i) Assay
            Development of each Project SNP, (ii) performance of Genotyping on
            the DNA Samples to provide AZ with a total of [*****] genotypes
            during the term of the Agreement, and (iii) compilation and
            dissemination to AZ of Assay Data with respect to the Project SNPs.

      1.15. "JSC" means the Joint Steering Committee described in Section 3 and
            established to review [*****] and aid in the development and
            oversight of the Collaboration.

[*****] CONFIDENTIAL MATERIAL OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. ASTERICKS DENOTE SUCH OMISSIONS

                                       3
<PAGE>

      1.16. "Non-Assay Failures" means failure to generate Assay Data as a
            result of performing Genotyping that is not related to Formatting or
            is outside the control of Orchid.

      1.17. "OB SNPs" means up to [*****] pursuant to Section 7.

      1.18. "Orchid Database" means Orchid's proprietary database [*****].

      1.19. "Orchid FTE Rate" means full-time employee manpower rate of (i)
            [*****] per annum for labor associated with Genotyping and [*****]
            per annum for labor associated with informatics (such as additional
            data or statistical analysis) that will be applied to work requested
            by AZ that is outside of the specific scope of this Agreement. All
            or any component of the Orchid FTE Rate may increase during the term
            of this Agreement, provided, however, that no Orchid FTE Rate may
            increase by more than 10% in any 12-month period, and provided
            further that Orchid will notify AZ in writing of any such increase
            prior to effectuating such increase.

      1.20. "Orchid Technology" means all patents, patent applications,
            copyrights, non-patented proprietary information, inventions,
            developments, techniques, materials, processes, manufactures,
            compositions of matter or methods of use and trade secrets, whether
            or not patentable or copyrightable, and other intellectual property
            owned or licensed by Orchid relating to SNP-IT (including any
            instruments, platforms, software, consumable SNP assay kits
            containing Primers and reagents or similar kits for Genotyping),
            Assay Development, Primer design and Formatting useful for
            performing SNP-IT and/or performing the services described in the
            Genotyping Studies and the PoP Study.

      1.21. [*****]

      1.22. [*****]

[*****] CONFIDENTIAL MATERIAL OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. ASTERICKS DENOTE SUCH OMISSIONS

                                       4
<PAGE>

      1.23. "Primers" mean primers useful in Orchid's SNP-IT method or PCR
            primers or information to generate PCR primers. Primers shall
            include any Primers designed by Orchid in connection with its
            providing Formatting services or other services pursuant to its
            performance of [*****] the Genotyping Studies or for any other
            purposes pursuant to this Agreement.

      1.24. "Project SNPs" means a panel of up to [*****].

      1.25. "SNP" means single nucleotide polymorphism.

      1.26. "SNP Criteria" means the following information and specifications:
            [*****]

      1.27. "SNP-IT(TM)" means an assay based on Orchid's proprietary primer
            extension technology that identifies one and only one base position
            of a target nucleic acid

      1.28. "Successful Conversion" or "Successfully Converted" means the
            conversion into working assays of at least [*****] of the SNP
            sequences provided to Orchid pursuant to this Agreement, [*****].
            Excluded from the calculation of Successful Conversion/Successfully
            Converted are (1) the [*****] genotypes utilized by Orchid for
            Formatting purposes, and (2) those SNPs that failed to convert as a
            result of a Non-Assay Failures.

2. SCOPE OF AGREEMENT.

      2.1.  The parties will enter into [*****] a Collaboration to conduct the
            Genotyping Studies on the terms and conditions set forth herein,
            pursuant to which Orchid will provide AZ with up to [*****] during
            the term of this Agreement.

      2.2.  AZ will pay to Orchid a total of not less than [*****] for the work
            to be performed by Orchid under [*****] the Genotyping Studies,
            consisting of an Access Fee and the annual payments described in
            Section 9. Orchid will provide AZ with additional services at any
            time during the term of this Agreement at AZ's request at the Orchid
            FTE Rate as provided in Section 11.

      2.3.  Within fifteen (15) days of the Effective Date, AZ will pay to
            Orchid the total Access Fee.

[*****] CONFIDENTIAL MATERIAL OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. ASTERICKS DENOTE SUCH OMISSIONS

                                       5
<PAGE>

3. JOINT STEERING COMMITTEE.

      3.1.  The parties will establish a JSC composed of two representatives
            from each of Orchid and AZ, to be appointed by each party
            respectively within thirty (30) days of the Effective Date.

      3.2.  Each party's representatives will serve at the discretion of such
            party and may be replaced at any time by such party.

      3.3.  Each party, by its representatives, will have one vote on the JSC.

      3.4.  The JSC will review [*****], develop the protocols and timelines for
            the Genotyping Studies and otherwise coordinate the work to be
            conducted under the Collaboration. JSC will also be responsible for
            monitoring `quality performance' (to be defined by the JSC at a
            later point [*****]) throughout the collaboration

      3.5.  The JSC will determine and submit to Orchid and AZ the work plans
            for the Collaboration including, without limitation, the protocols
            and timelines to be followed by the parties in the performance of
            the Genotyping Studies (including the parameters for performance of
            the Genotyping and the format of such parameters), together with the
            responsibilities of each party, where possible by the Collaboration
            Start Date (as defined in Section 5.1), or otherwise on an on-going
            basis.

      3.6.  Orchid will provide the JSC with a schedule of the Orchid FTE Rate
            by the Collaboration Start Date. Such schedule will be incorporated
            into the JSC's work plans.

      3.7.  The JSC may at any time during the term of the Agreement make
            modifications to the work plans that, in its reasonable discretion,
            it believes is necessitated by sound business or scientific reasons,
            provided that, the JSC may not, under any circumstances, modify the
            minimum or maximum number of genotypes, the amount of any payment
            (including the Access Fee) set forth herein or the Orchid FTE Rate.

      3.8.  All work plans and any permitted modification thereto submitted by
            the JSC will be attached to this Agreement as Schedule B and made a
            part hereof.

[*****] CONFIDENTIAL MATERIAL OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. ASTERICKS DENOTE SUCH OMISSIONS

                                       6
<PAGE>

      3.9.  The initial meeting of the JSC will occur at a site determined by
            Orchid no later than thirty (30) days after the Effective Date.
            Thereafter, during the term of this Agreement, the JSC will meet
            once in each three-month period or at such other periodic intervals
            as the JSC may determine is necessary or appropriate from time to
            time.

      3.10. After the initial meeting, the site of JSC meetings will alternate
            between the offices of AZ and Orchid (or any other site or by
            teleconference as mutually agreed upon by the JSC).

      3.11. The proceedings of all meetings of the JSC will be summarized in
            writing and sent to both parties. The party hosting the meeting will
            be responsible for the preparation and circulation of such
            summaries.

      3.12. Each party will bear all expenses of their respective JSC
            representatives related to their participation on the JSC and
            attendance at JSC meetings.

4. [*****]

      4.1.  [*****].

      4.2.  [*****].

      4.3.  [*****].

      4.4.  [*****].

      4.5.  [*****].

      4.6.  [*****].

      4.7.  [*****].

      4.8.  [*****].

      4.9.  [*****].

      a.    [*****].

[*****] CONFIDENTIAL MATERIAL OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. ASTERICKS DENOTE SUCH OMISSIONS

                                       7
<PAGE>

      4.13. [*****].

      4.14. [*****].

      4.15. [*****].

5. THE COLLABORATION.

      5.1.  The Collaboration will commence on [*****] ("Collaboration Start
            Date") and be completed within the term of this Agreement.

      5.2.  Notwithstanding the JSC's discretion to develop the work plans for
            the Collaboration, the parties agree that the objectives of the
            Collaboration will be as follows:

                  Year  1: [*****];

                  Year  2: [*****]; and

                  Year  3: [*****].

6. GENOTYPING STUDIES.

      6.1.  AZ will select the Project SNPs and will provide to the JSC its
            criteria for the Genotyping Studies (i.e. which Project SNPs will be
            run on which DNA Samples) pursuant to the timelines and other
            criteria set forth by the JSC in a work plan to be provided by the
            JSC.

      6.2.  AZ will provide Orchid with the relevant Project SNPs and the
            applicable DNA Samples no later than the date specified by the JSC
            in the work plans.

      6.3.  AZ will (through the JSC) assist in augmenting the OB Database,
            including providing recommendations as to its composition.

      6.4   Orchid will use reasonable commercial efforts to perform the
            Genotyping Studies in accordance with the date(s) set forth in the
            work plans provided by the JSC,

[*****] CONFIDENTIAL MATERIAL OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. ASTERICKS DENOTE SUCH OMISSIONS

                                       8
<PAGE>

            provided that AZ makes all payments due hereunder. AZ recognizes,
            however, that Formatting and Genotyping involve a number of
            technologically complex steps and are dependent upon the quality of
            the submitted Project SNPs and DNA Samples. Accordingly, the time
            periods set forth by the JSC in the work plans for the completion of
            each step are approximate and subject to variation due to
            technological difficulties that may be encountered in the
            performance of the Genotyping Studies.

      6.5.  Orchid will supply all raw materials, other than the AZ SNPS and the
            DNA Samples (all of which will be provided by AZ at its sole cost
            and expense), necessary to perform the Genotyping Studies, including
            reagents and Primers; provided, however, that Orchid may, in its
            sole discretion, use amplification primers provided by AZ to Orchid.

7. ASSAY DEVELOPMENT PHASE.

      7.1.  The Assay Development phase of the Genotyping Studies will be
            performed only on the Project SNPs selected by AZ for such purpose
            in accordance with the JSC's work plans.

      7.2.  AZ will select the OB SNPs from the Orchid Database, [*****].

      7.3.  In accordance with any timelines developed by the JSC, AZ will
            provide to Orchid at least [*****] AZ SNPs for the Assay Development
            phase of the Genotyping Studies and Orchid will perform Assay
            Development for each submitted AZ SNP to achieve Successful
            Conversion [*****].

      7.4.  Orchid will use up to [*****] genotypes for conducting and
            validating the Assay Development phase of the Genotyping Studies.

8. GENOTYPING PHASE.

      8.1.  Orchid will perform the Genotyping phase of the Genotyping Studies
            on submitted DNA Samples for SNPs that have been Successfully
            Converted to provide AZ with [*****] genotypes during the term of
            the Agreement, [*****].

      8.2.  [*****].

[*****] CONFIDENTIAL MATERIAL OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. ASTERICKS DENOTE SUCH OMISSIONS

                                       9
<PAGE>

      8.3.  [*****].

9. PAYMENTS.

      9.1.  In addition to the Access Fee, AZ will pay Orchid a nonrefundable,
            noncreditable annual fee equal to [*****] on each of the first and
            second anniversaries of the Effective Date.

      9.2.  The annual fees will be payable ([*****]) to Orchid by AZ as
            follows:

                  9.2.1. [*****];

                  9.2.2. [*****], and

                  9.2.3. [*****].

      9.3.  All payments hereunder will be made by AZ in United States Dollars
            by wire transfer of funds to an account designated by Orchid or by
            delivery of an irrevocable cashier's check to Orchid. The following
            is wire transfer information for Orchid's bank:

                  Bank Name:     [*****]
                  Bank Address:  [*****]
                  ABA #:         [*****]
                  Account Name:  [*****]
                  Account #:     [*****]

10. RECORDS AND REPORTING OF RESULTS.

      10.1. Orchid will keep accurate and complete records during its
            performance of the Genotyping Studies in order to compile and
            provide to AZ the Assay Data.

      10.2. Orchid will provide AZ with the Assay Data in accordance with the
            timelines set forth by the JSC in the work plans.

      10.3. Notwithstanding the foregoing, Orchid will have no obligation to
            provide AZ with any Assay Data unless it has received from AZ
            payment of all of the then due

[*****] CONFIDENTIAL MATERIAL OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. ASTERICKS DENOTE SUCH OMISSIONS

                                       10
<PAGE>

            fees, other than the balance of the annual fee due pursuant to
            Section 9.2.

      10.4. Orchid will submit the Assay Data to AZ to the address and in the
            manner reasonably specified by the JSC to Orchid. AZ will select the
            courier service, if necessary, for the delivery of the Assay Data,
            and Orchid will pay for the courier service but will not be liable
            for any damages, loss or penalty for delay or failure in delivery
            caused by such service.

11. ADDITIONAL WORK.

      11.1. From time to time during the term of this Agreement, AZ may request,
            directly or through the JSC, (i) a modification, addition,
            supplement or other change in the work plan of the JSC or the
            services provided by Orchid hereunder, (ii) additional data
            including additional information concerning the Formatted SNP Data;
            (iii) additional Formatting, reports, Genotyping, consulting,
            presentations or other support (collectively, the "Additional
            Work"), none of which is covered by this Agreement.

      11.2. AZ will submit its request through the JSC. The JSC will, to the
            extent relevant and necessary, provide the timeline, protocols and
            other specifications for such Additional Work.

      11.3. Orchid will perform such Additional Work for AZ at the then
            prevailing Orchid FTE Rate. Orchid will submit an invoice for the
            total amount due for the Additional Work upon completion (unless
            otherwise defined by the JSC in an approved plan) and AZ will pay
            Orchid the amount invoiced within 30 days.

12. LIMITED OR NO LICENSE.

      12.1. Subject to clauses 16.1 and 16.2, AZ grants to Orchid a paid-up,
            royalty-free, worldwide, non-exclusive, non-sublicensable,
            non-assignable license to use the AZ SNPs and DNA Samples received
            from AZ under this Agreement solely for the purpose of performing
            [*****] the Genotyping Studies (including, without limitation,
            including AZ SNPs in the Orchid Database).

[*****] CONFIDENTIAL MATERIAL OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. ASTERICKS DENOTE SUCH OMISSIONS

                                       11
<PAGE>

      12.4. Subject to 16.1 and 16.2, no other license is intended or granted
            through delivery of the Project SNPs and DNA Samples.

      12.5. The performance of [*****] the Genotyping Studies for AZ by Orchid
            does not include or carry any right or license, express or implied,
            in or to any Orchid Technology.

      12.6. AZ acknowledges that Orchid commercializes Primers and Orchid
            Technology. AZ further acknowledges and agrees that Orchid intends,
            and is permitted, to sell and otherwise commercialize Primers and
            Orchid Technology (with no obligation to AZ) that may be generated
            (whether or not an invention) as a result of or in connection with
            the performance by Orchid of the Genotyping Studies. This paragraph
            12.5 survives any termination or expiration of this Agreement.

13. INTELLECTUAL PROPERTY.

      13.1  As between Orchid and AZ, Orchid has sole ownership of, and retains
            all right, title and interest to, the Orchid Technology.

      13.2  AZ has sole ownership of, and retains all right, title and interest
            to, the AZ SNPS, and Assay Data subject only to Orchid's limited
            license set forth in Section 12.1.

      13.3  Any intellectual property developed by AZ through the use of Assay
            Data will be the sole property of AZ.

14. REPRESENTATIONS AND WARRANTIES; DISCLAIMERS AND LIMITATIONS ON LIABILITY.

      14.1. OTHER THAN AS EXPRESSLY SET FORTH IN THIS AGREEMENT AND THE
            SCHEDULES TO THIS AGREEMENT, ORCHID MAKES NO REPRESENTATIONS,
            GUARANTIES OR WARRANTIES, EXPRESS OR IMPLIED, TO AZ REGARDING THE
            RESULTS FROM ITS PERFORMANCE OF [*****] THE GENTOYPING STUDIES OR
            THE USE, OR THE RESULTS OF THE USE OF ANY ASSAY DATA, INCLUDING ANY
            WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND

[*****] CONFIDENTIAL MATERIAL OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. ASTERICKS DENOTE SUCH OMISSIONS

                                       12
<PAGE>

            NONE ARE CREATED, WHETHER UNDER THE UNIFORM COMMERCIAL CODE, CUSTOM
            OR USAGE IN THE INDUSTRY OR THE COURSE OF DEALINGS BETWEEN THE
            PARTIES.

      14.2. AZ REPRESENTS AND WARRANTS THAT ANY STATEMENTS HERETOFORE OR
            HEREAFTER MADE BY ORCHID OR ANY OF ITS REPRESENTATIVES RELATIVE TO
            THE USE OR THE RESULTS OF THE USE OR THE ASSAY DATA OR THE
            PERFORMANCE OF [*****] THE GENOTYPING STUDIES WILL ALWAYS BE
            INDEPENDENTLY VERIFIED BY AZ AND AZ AGREES THAT ITS ACCEPTANCE
            AND/OR USE OF SUCH STATEMENTS IS ENTIRELY AT ITS OWN RISK.

      14.3. ORCHID MAKES NO WARRANTY OR REPRESENTATION TO AZ THAT THE USE OF ANY
            ASSAY DATA OR ANY PRODUCT PRODUCED BY SUCH USE, WILL NOT INFRINGE
            ANY PATENT, COPYRIGHT, TRADE SECRET, OR OTHER PROPRIETARY RIGHT,
            FOREIGN OR DOMESTIC, OF ANY THIRD PARTY TO WHICH ORCHID HAS NOT
            OBTAINED RIGHTS.

      14.4. ORCHID WILL NOT BE LIABLE TO AZ OR ITS AFFILIATES, CUSTOMER'S
            SUCCESSORS OR ASSIGNS OR ANY THIRD PARTY WITH RESPECT TO ANY CLAIM
            FOR LOSS OF PROFITS, LOSS OR INTERRUPTION OF BUSINESS, OR FOR
            INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES OF ANY KIND.

      14.5. AZ represents to Orchid that: it is duly organized, validly existing
            and in good standing under the laws of England; it has the power and
            requisite authority to deliver the AZ SNPS and DNA Samples to Orchid
            pursuant to this Agreement; it has taken all actions necessary to
            secure all approvals required to be secured by it in connection with
            the transactions contemplated hereby; the execution, delivery and
            performance of this Agreement has been duly authorized by all
            necessary corporate and other action; this Agreement has been duly
            executed and delivered and constitutes its legal, valid and binding
            obligation, enforceable against it in accordance with its terms; the
            execution, delivery and performance of this

[*****] CONFIDENTIAL MATERIAL OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. ASTERICKS DENOTE SUCH OMISSIONS

                                       13
<PAGE>

            agreement does not violate any agreement to which it is a party or
            by which it is bound or any law, order or decree applicable to it,
            or any provision of its charter documents or bylaws.

      14.6. Orchid represents to AZ that: it is duly organized, validly existing
            and in good standing under the laws of the State of Delaware; it has
            taken all actions necessary to secure all approvals required to be
            secured by it in connection with the transactions contemplated
            hereby; the execution, delivery and performance of this Agreement
            has been duly authorized by all necessary corporate and other
            action; this Agreement has been duly executed and delivered and
            constitutes its legal, valid and binding obligation, enforceable
            against it in accordance with its terms; the execution, delivery and
            performance of this Agreement does not violate any agreement to
            which it is a party or by which it is bound or any law, order or
            decree applicable to it, or any provision of its charter documents
            or bylaws.

15. INDEMNIFICATION.

      15.1. Orchid agrees to indemnify, defend, and hold harmless AZ and its
            directors, officers, agents, employees, representatives and assigns,
            from and against all liabilities, damages, expenses and losses
            (including reasonable attorney fees and costs), arising out of the
            gross negligence or willful misconduct of Orchid, its employees or
            any third party acting on behalf or under authority of Orchid in the
            performance of this Agreement.

      15.2. Notwithstanding the foregoing, Orchid will not be liable to AZ or
            any of its successors or assigns, or to any third party with respect
            to any use of the Assay Data, or any loss, claim, damage or
            liability of any kind or nature which may arise from or in
            connection with the use of the Assay Data or any products resulting
            from such use; or for any claim for loss of profits, loss or
            interruption of business, or for indirect, special or consequential
            damages of any kind.

      15.3. AZ agrees to indemnify, defend and hold harmless Orchid, its
            Affiliates and their respective directors, officers, agents,
            employees, representatives, successors and assigns, from and against
            all liabilities, demands, damages, expenses and losses (including
            reasonable attorney fees and costs) and any actual or alleged act of
            patent infringement, contributory patent infringement, inducing
            patent infringement, or copyright infringement arising out of or
            resulting from (i) AZ's or any third party's use of the Assay Data,
            (ii) any products developed or made by

                                       14
<PAGE>

            AZ or any third party as a result of the use of the Assay Data, and
            (iii) AZ's delivery to Orchid of AZ SNPs and DNA Samples.

      15.4. A party seeking indemnification under this Agreement will give
            prompt written notice to the indemnifying party of the commencement
            of any action (and any prior claims relating to such action) for
            which the party seeks indemnification. An indemnifying party will
            have no liability or responsibility of any kind to the party seeking
            indemnification if it is not promptly notified and does not have
            adequate opportunity to defend. The indemnifying party will have
            sole control of the defense of the action and of all negotiations
            for its settlement or compromise.

      15.5. This section 15 survives any termination or expiration of this
            Agreement.

16. CONFIDENTIALITY.

      16.1. Orchid agrees that with respect to AZ SNPs that are not OB SNPs,SNPs
            independently provided to Orchid by any third party and/or SNPs of
            The SNP Consortium, Ltd., Orchid will not make such AZ SNPs
            available to any third party (whether through the Orchid Database or
            otherwise) and will treat such SNPs as Confidential Information for
            a period of 15 months from the First Use of such AZ SNP (the
            "Standstill Period"). Orchid may use public domain AZ SNPs for
            internal research purposes so long as the identification of such
            SNPs and the subsequent research into drug development and/or
            adverse drug reactions is independently derived (supportable and
            verified by documents) by Orchid and not derived from any
            information gained from AZ through this collaboration. Orchid will
            not make available to third parties any public domain AZ SNPs.

      16.2. Subsequent to the Standstill Period, any such AZ SNP may be used by
            Orchid and/or made available by Orchid to third parties, unless,
            prior to the expiration of the Standstill Period, AZ notifies Orchid
            in writing that it wishes to extend the Standstill Period and pays
            Orchid [*****] per SNP within 15 days of such notification. In such
            event, the Standstill Period will be extended indefinitely with
            respect to those selected AZ SNPs.

      16.3. Notwithstanding Sections 16.1 and 16.2, Orchid may perform any
            service or enter into any collaboration or research project with
            respect to a SNP submitted to

[*****] CONFIDENTIAL MATERIAL OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. ASTERICKS DENOTE SUCH OMISSIONS

                                       15
<PAGE>

            Orchid by any third party after the Effective Date that is the same
            SNP as an AZ SNP.

      16.4. Orchid and AZ each agrees that it will keep confidential, and will
            cause its employees, consultants, Affiliates and licensees to keep
            confidential, and will not transfer or disclose to any third party,
            and will not use for any purpose other than the purposes
            contemplated by this Agreement, any Confidential Information of the
            other party.

      16.5. Each Receiving Party's nondisclosure obligation will not apply to
            information that is:

            16.5.1. already known to the Receiving Party at the time of its
                    disclosure or communication, to the extent evidenced by
                    written documentation;

            16.5.2. becomes published or otherwise part of the public domain
                    through no fault of the Receiving Party;

            16.5.3. disclosed to the Receiving Party by any third party not
                    under an obligation of confidentiality;

            16.5.4. required, by law, regulation or action of any governmental
                    agency or authority, to be disclosed, provided the Receiving
                    Party complies with Section 16.3 ; or

            16.5.5  disclosed by the Receiving Party with the prior written
                    consent of the Disclosing Party.

            16.5.5  independently generated by the Receiving Rarty.

      16.6. If either party becomes legally compelled to disclose Confidential
            Information of the other, the Receiving Party will provide the
            Disclosing Party with prompt notice so that the Disclosing Party may
            seek a protective order or other appropriate remedy and/or waive
            compliance with the provisions of this Agreement. If in the absence
            of a protective order or the receipt of a waiver, the Receiving
            Party nevertheless is legally required to disclose Confidential
            Information of the other to any governmental authority or court of
            competent jurisdiction, or else stand liable for contempt or suffer
            other censure or penalty, the Receiving Party may disclose such
            Confidential Information, to the most

                                       16
<PAGE>

            protected and limited extent feasible, without liability under this
            Agreement.

      16.7. This Section 16 survives any termination or expiration of this
            Agreement.

17. TERM AND TERMINATION .

      17.1. Unless extended by mutual agreement, this Agreement will expire and
            terminate three (3) years after the Effective Date.

      17.2. Each party has the right to terminate this Agreement forthwith upon
            written notice to the other party if any proceeding is instituted by
            or against the other party seeking to adjudicate it bankrupt or
            insolvent, or seeking liquidation, winding up, reorganization,
            rearrangement, adjustment, protection, relief or composition of it
            or its debts under any law relating to bankruptcy, insolvency or
            reorganization or relief of debtors, or seeking an entry of an order
            for relief or the appointment of a receiver, trustee or other
            similar official for it or any substantial part of its property or
            taking any action to authorize any of the foregoing or similar
            actions. No assignee for the benefit of creditors, receiver,
            liquidator, sequestator, trustee in bankruptcy, sheriff or any other
            office of the court or official charged with taking over custody of
            AZ's assets or business will have any right to compel Orchid to
            continue the performance of this Agreement.

      17.3. [*****].

      17.4. [*****].

      17.5. Orchid has the right to terminate this Agreement if AZ fails to make
            any payment due and owing, or commits a breach of any other material
            provision of this Agreement and fails to make such payment or remedy
            such breach within sixty (60) days after receiving written notice of
            such default or breach.

      17.6  Upon termination of this Agreement for any reason, Orchid will
            promptly return to AZ any unused DNA Samples in its possession, but
            will have no obligation to complete any Formatting or other service
            on the AZ SNPS nor to compile and deliver any Assay Data not
            previously complied.

[*****] CONFIDENTIAL MATERIAL OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. ASTERICKS DENOTE SUCH OMISSIONS

                                       17
<PAGE>

      17.7  On termination, AZ will have no further obligations for the payment
            of fees.

18. ANNOUNCEMENTS.

      18.1. AZ and Orchid will make public a joint press release in the form
            attached as Schedule D within ten (10) days of execution of the
            Effective Date.

19 PUBLICATIONS.

            AZ will be free to make scientific publication of the Assay Data.In
            such written publications where the use of Orchid technology is
            described, AZ will provide Orchid with drafts of the publications at
            least thirty (30) days prior to its submission or presentation, and
            accord Orchid with credit and/or right of co-authorship where
            appropriate. If the draft discloses any trade secrets or inventions
            of Orchid, AZ will delete such disclosures and delay publication up
            to 60 days to allow Orchid to draft and file patent applications on
            any disclosed patentable inventions prior to publication. This
            Section 19 survives any termination or expiration of this Agreement.

20. DISPUTE RESOLUTION.

      20.1. In the event the JSC is deadlocked with respect to any decision of
            the JSC, or in the event of any other controversy or claim relating
            to, arising out of or in any way connected to any provision of this
            Agreement ("Dispute"), the Dispute will be submitted to the senior
            official of each party designated below for attempted resolution:

                  For Orchid: CEO

                  For AZ:Head of Global Enabling Science & Technology Group

      20.2  If the designated senior officials of each party are unable to
            resolve the Dispute within sixty (60) days after good faith
            negotiation, the dispute resolution provisions of Section 20.4 will
            apply, unless the dispute is related solely to a question of
            scientific interpretation or otherwise involves only scientific or

                                       18
<PAGE>

            technological issues [*****] ("Scientific Dispute"). In the event of
            a Scientific Dispute, the parties will resolve that matter through
            the use of an expedited mediation process, in which the parties
            first try to agree on a mutually acceptable scientist to serve as
            the mediator (failing mutual agreement on a single scientist, each
            party appoints a scientist not affiliated with such party and the
            two so selected pick a third unaffiliated scientist) within 30 days.
            The mediator(s) will review the disputed matter on an expedited
            basis (not to exceed 45 days), considering the relevant data,
            standards established by this Agreement, and any work plans. The
            decision of the mediator(s) will be binding on the parties.

      20.3. If the Dispute is not resolved by the designated senior officials of
            each party within 60 days in accordance with Section 20.2, or if
            such senior officials fail to meet within such time period, either
            party may seek arbitration under the rules of the American
            Arbitration Association ("AAA Rules") pursuant to Section 21.5.

      20.4. Whenever a party decides to institute arbitration proceedings, it
            will give written notice to that effect to the other party. The
            arbitration proceeding will be held in Delaware. The arbitration
            will be conducted before a single arbitrator mutually chosen by the
            parties, but if the parties have not agreed upon a single arbitrator
            within fifteen (15) days after notice of the institution of the
            arbitration proceeding, then the arbitration will be conducted by a
            panel of three arbitrators, one chosen by each party with the third
            chosen by the other two arbitrators. No arbitrator (nor the panel of
            arbitrators) will have the power to award punitive damages or any
            award of multiple damages under this Agreement and such awards are
            expressly prohibited. Decisions of the arbitrator(s) will be final
            and binding on the parties.

      20.5. Notwithstanding the foregoing, nothing in this Article 2 will be
            construed as limiting in any way the right of a party to seek
            injunctive, equitable or other relief from a court of competent
            jurisdiction. Both AZ and Orchid consent to the personal
            jurisdiction and venue of the United States District Court for the
            District of New Jersey; and such court will have exclusive
            jurisdiction over any Dispute. AZ and Orchid both further consent
            that any process or notice of motion or other application to the
            court or Judge thereof may be served outside the State of New

[*****] CONFIDENTIAL MATERIAL OMITTED AND FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION. ASTERICKS DENOTE SUCH OMISSIONS

                                       19
<PAGE>

            Jersey by registered or certified mail or by personal service,
            provided a reasonable period of time for appearance is allowed.

21. MISCELLANEOUS.

      21.1. Orchid, in its performance of this Agreement, may delegate its
            obligations or duties to one or more Affiliates, agent(s),
            subcontractors or licensees; provided that no such Affiliate, agent,
            subcontractor or licensee will have the right or authority to make
            any representation or warranty to AZ, or to assume or create any
            obligations with or for AZ, whether express or implied, on behalf or
            in the name of Orchid. In the event Orchid does delegate any
            obligation or duty to an Affiliates, agent(s), subcontractors or
            licensees, Orchid shall not be relieved of its responsibility for
            the terms of this agreement as it pertains to such delegated
            obligation or duty.

      21.2. This Agreement is binding upon and inures to the benefit of the
            heirs, successors and assigns of the parties hereto.

      21.3. The rights provided herein are personal to the parties and may not
            be assigned or otherwise transferred without the prior express
            written approval of the other party, except that either party may
            assign this Agreement to any Affiliate or any successor by merger or
            sale of substantially all of its business or assets to which this
            Agreement pertains, without any such consent. Any assignment in
            violation hereof is void. Notwithstanding the foregoing, Orchid
            agrees that AZ may terminate this Agreement immediately upon the
            merger or sale of substantially all of its business or assets to
            which this Agreement pertains to a direct competitor of AZ in the
            field of drug discovery.

      21.4. This Agreement will be governed by the laws of the State of New
            Jersey (excluding the principles of conflict of laws and the 1980 UN
            Convention on Contracts for the International Sale of Goods).

      21.5. In the event that either party is prevented from performing or is
            unable to perform any of its respective obligations under this
            Agreement due to any act of God, fire, casualty, flood, war, strike,
            lockout, failure of public utilities, injunction; or any act,
            exercise, assertion or requirement of governmental authority,
            epidemic, destruction of production facilities, riots, insurrection,
            inability to procure or use materials, labor, equipment,
            transportation or energy; or any other cause beyond the reasonable
            control of a party, such party will give notice to the other party
            in

                                       20
<PAGE>

            writing promptly, and if the affected party will have used its
            commercially reasonable best efforts to avoid such occurrence, its
            performance will thereafter be excused and the time for performance
            will be extended for the period of delay or inability to perform due
            to such occurrence.

      21.6. Any notice required or permitted under this Agreement will be deemed
            to have been sufficiently provided, and effective on the date of
            receipt, if sent by facsimile and either hand-delivered or sent by
            overnight express courier (e.g. Federal Express) and addressed to
            the receiving party at its respective address as follows:

                             If  to AZ:
                             AstraZeneca UK Limited
                             15 Stanhope Gate
                             London
                             W1K 1LN
                             United Kingdom

                             With a copy to:
                             AstraZeneca UK Limited
                             Alderley House, Alderley Park
                             Macclesfield, Cheshire
                             SK10 4TF
                             United Kingdom
                             Attn: Legal Department

                             If to Orchid:

                             Orchid BioSciences, Inc.
                             303 College Road East
                             Princeton, New Jersey 08540
                             Attention:  Kevin Nash, Esq.
                             With a copy to:

                             Kalow & Springut LLP
                             488 Madison Avenue
                             New York, New York 10022
                             Attention: David A. Kalow, Esq.

                                       21
<PAGE>

            or such other address as is provided pursuant to this Section.

      21.7. The relationship of Orchid and AZ under this Agreement is that of
            independent contractors. The provisions of this Agreement will not
            be construed to create between Orchid and AZ the relationship of
            principal and agent, joint venturers, co-partners or any other
            similar relationship, the existence of which is hereby denied by
            Orchid and AZ. Orchid is not an agent for AZ and AZ is not an agent
            for Orchid for any purpose whatsoever and each party has no right or
            authority to assume or create any obligations, express or implied,
            on behalf or in the name of the other party.

      21.8. Neither party will be liable in any way for any engagement,
            obligation, liability, contract, representation or warranty of the
            other party to or with any third party.

      21.9. If any provision of this Agreement is held to be invalid, illegal,
            unenforceable or void, such provision will be without effect on the
            validity, legality and enforceability of the remaining provisions or
            this Agreement as a whole. Both parties will endeavor to replace the
            invalid, illegal, unenforceable or void provision with a valid and
            enforceable one that in its equitable effect is most consistent with
            the prior provision.

     21.10. No amendment, variation, waiver or modification of any of the terms
            or provisions of this Agreement will be effected unless set forth in
            writing, specifically referencing this Agreement, and duly signed by
            an authorized officer of the party to be bound thereby.

     21.11. The section and paragraph headings and numbering are for
            convenience only and cannot have any effect on the interpretation or
            construction of this Agreement.

     21.12. Each party acknowledges and agrees that (i) this Agreement together
            with the attached Schedules constitutes the complete and exclusive
            understanding between the parties, which supersedes and merges all
            prior proposals, term sheets, understandings and all other
            agreements, oral and written, between the parties regarding the
            subject matter of this Agreement; and (ii) no party has relied on
            any representation not expressly set forth or referred to in this
            Agreement.

     21.13. This Agreement may be executed in two or more counterparts, all of
            which constitute one and the same legal instrument.

                                       22
<PAGE>

      21.14 Each Party acknowledges and agrees that: (i) its counsel reviewed
            and negotiated the terms and conditions of this Agreement and have
            contributed to its revision; (ii) it understands and agrees to be
            bound by the terms and conditions of this Agreement; (iii) the rule
            of construction to the effect that any ambiguities are resolved
            against the drafting party will not be employed in the
            interpretation of this Agreement; and (iv) the terms and provisions
            of this Agreement will be construed fairly as to all parties hereto
            and not in a favor of or against any party, regardless of which
            party was generally responsible for the preparation of this
            Agreement.

      21.15 AZ and Orchid agree to execute, acknowledge, and deliver such
            further instruments and do all other such acts as may be necessary
            or appropriate to effect the purpose and intent of this Agreement.

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective
Date.

ASTRAZENECA UK LIMITED                            ORCHID BIOSCIENCES, INC.

By: /s/ Iain Ward                                 By: /s/ Donald R. Marvin
    -----------------------------                     --------------------------

Title: Authorized Signatory                      Title: SVP, COO & CFO
       --------------------------                       ------------------------

                                       23
<PAGE>

                                   SCHEDULE A

                               DNA Sample Criteria

 Include all specifications and other requirements for properly obtained samples

                                       24
<PAGE>

                                   SCHEDULE B

                        Workplans for Genotyping Studies

                                  (TBD by JSC)

                               cannot be included

                                       25
<PAGE>

                                   Schedule C

                              Sample Press Release

                                       26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}]]